Modification of the physical state of low soluble drugs, as amorphization, is a promissory strategy to increase their solubility, since this intrinsically disordered state promotes solubilisation. In the present work, a composite has been prepared and characterized aiming to improve the aqueous solubility of a drug by amorphization, and able to be used for controlled drug delivery. Simvastatin (SIM) is the target drug, belonging to statins family, used to reduce the levels of cholesterol in blood and with high efficiency in bone regeneration. To achieve SIM’s amorphization, it was incorporated in unmodified and surface treated by methylation SBA-15 mesoporous matrices. Nuclear magnetic resonance and infrared spectroscopy together with ther...
The coprocessing of active pharmaceutical ingredient (API) with an excipient which has a high glass ...
The coprocessing of active pharmaceutical ingredient (API) with an excipient which has a high glass ...
Poor aqueous solubility is an issue not only in drug discovery and development but also for register...
Amorphization technology has been the subject of continuous attention in the pharmaceutical industry...
The high index of simultaneous incidence of hypertension and hypercholesterolemia in the population ...
The coprocessing of active pharmaceutical ingredient (API) with an excipient which has a high glass ...
Many pharmaceutical compounds are quite insoluble in their crystalline state. As a consequence, ther...
In this paper, the role of mesoporous silica (MS) particle size in the stabilization of amorphous s...
Interest in amorphous pharmaceutical systems is steadily growing over the last 10 years. The amorph...
Due to their unique qualities such as biocompatibility, ability to be tuned to suit different drug...
Amorphous formulation technologies to improve oral absorption of poorly soluble active pharmaceutica...
Amorphous formulation technologies to improve oral absorption of poorly soluble active pharmaceutica...
The formulation of poorly water-soluble drugs is one of the main challenges in the pharmaceutical in...
An attractive, yet challenging approach to overcome poor water solubility is to convert a crystallin...
INTRODUCTION: Poor aqueous solubility of active pharmaceutical ingredients (APIs) is one of the main...
The coprocessing of active pharmaceutical ingredient (API) with an excipient which has a high glass ...
The coprocessing of active pharmaceutical ingredient (API) with an excipient which has a high glass ...
Poor aqueous solubility is an issue not only in drug discovery and development but also for register...
Amorphization technology has been the subject of continuous attention in the pharmaceutical industry...
The high index of simultaneous incidence of hypertension and hypercholesterolemia in the population ...
The coprocessing of active pharmaceutical ingredient (API) with an excipient which has a high glass ...
Many pharmaceutical compounds are quite insoluble in their crystalline state. As a consequence, ther...
In this paper, the role of mesoporous silica (MS) particle size in the stabilization of amorphous s...
Interest in amorphous pharmaceutical systems is steadily growing over the last 10 years. The amorph...
Due to their unique qualities such as biocompatibility, ability to be tuned to suit different drug...
Amorphous formulation technologies to improve oral absorption of poorly soluble active pharmaceutica...
Amorphous formulation technologies to improve oral absorption of poorly soluble active pharmaceutica...
The formulation of poorly water-soluble drugs is one of the main challenges in the pharmaceutical in...
An attractive, yet challenging approach to overcome poor water solubility is to convert a crystallin...
INTRODUCTION: Poor aqueous solubility of active pharmaceutical ingredients (APIs) is one of the main...
The coprocessing of active pharmaceutical ingredient (API) with an excipient which has a high glass ...
The coprocessing of active pharmaceutical ingredient (API) with an excipient which has a high glass ...
Poor aqueous solubility is an issue not only in drug discovery and development but also for register...